App-Quantinova.ai

Spatially resolved transcriptomics deconvolutes histological prognostic subgroups in patients with colorectal cancer and synchronous liver metastases.

Colin Wood - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Interleukin-10

Clinical performance of Immunoscore in stage III colorectal cancer patients in the SCOT and IDEA-HORG cohorts.

David Church - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

mFOLFOX6

Early-onset colorectal cancer: Real-world genomic data from the community-based Sarah Cannon Cancer Centers Network.

Elisa Fontana - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient non-endometrial solid tumors: A post-hoc subgroup analysis of patients with colorectal cancer.

Thierry Andre - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).

Scott Kopetz - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Encorafenib

A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors.

Debashis Sarker - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tipiracil and trifluridine

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

Kanwal Pratap Singh Raghav - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Trastuzumab

Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomized phase II trial (PRIME-RT).

Catherine Ruth Hanna - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Jean-Philippe Metges - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Pembrolizumab

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

Zev A. Wainberg - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Pembrolizumab

John A. Bridgewater - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Ipilimumab

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Yelena Y. Janjigian - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Trastuzumab

Assessment of changes in chest wall mechanics in esophageal cancer survivors using a 3D-motion capture system.

Karina Tukanova - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

N/A

SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.

David S. Hong - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neoplastic meningitis

Cyclophosphamide

A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.

Luhua Wang - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Fluorouracil

SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.

Karyn A. Goodman - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Atezolizumab

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.

Do-Youn Oh - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Gemcitabine

Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.

Gregory Naylor - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Regorafenib

Natural history of patients with advanced cholangiocarcinoma and FGFR2 gene fusions/rearrangements.

Rachna T. Shroff - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis.

Antonio D'Alessio - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

Atezolizumab

Filters

45280 Abstracts